The collaboration integrates Demeetra’s CleanCut CHO platforms and cell line services with NorthX Biologics’ GMP ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, ...
BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...
Over the last few years, RNA-encapsulated lipid nanoparticles (RNA-LNPs) have emerged as a new drug modality with the potential to change the pace of biopharmaceutical innovation. GMP manufacturing of ...
Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture replacement organs and cellular therapies. Many groups have shown therapeutic ...
SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (PRRUF) (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Discover proven strategies and innovative technologies to streamline microbial development, from early studies to GMP readiness. Learn from industry experts how to boost productivity, overcome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results